AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 24726159
Drug: Balanced salt
RxNorm normalized name: Balanced Salt Solution
DrugBank: Magnesium chloride (DB09407)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Balanced salt solution applied for 15 seconds (Control)
Trial: 23264316
Drug: Oxymorphone ER
RxNorm normalized name: oxymorphone Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxymorphone ER (20 mg)
Trial: 12376581
Drug: rosiglitazone (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rosiglitazone (8 mg/day, 2 divided doses)
Trial: 9456163
Drug: Isradipine (calcium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isradipine (calcium channel blocker)
Trial: 9456163
Drug: Both treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatments (Isradipine and Placebo)
Trial: 30910569
Drug: Massage therapy
RxNorm normalized name: CAMPHOR (SYNTHETIC) 30 g in 1 mL / MENTHOL 40 g in 1 mL TOPICAL OIL [CBDMEDIC MASSAGE THERAPY]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Massage therapy (10 minutes to the quadriceps)
Trial: 16480565
Drug: Cognitive-behaviour therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behaviour therapy group programme for social phobia (10 sessions)
Trial: 17561562
Drug: Topical betamethasone
RxNorm normalized name: betamethasone Topical Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical betamethasone 0.1%
Trial: 27015572
Drug: Topical nepafenac
RxNorm normalized name: Nepafenac
DrugBank: Nepafenac (DB06802)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical nepafenac 0.1%
Trial: 31638843
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no anti-inflammatory agent)
Trial: 10974130
Drug: Indomethacin (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin (0.2 mg/kg, given at 12-hour intervals)
Trial: 10974130
Drug: Ibuprofen (first
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen (first dose of 10 mg/kg, followed by two doses of 5 mg/kg at 24-hour intervals)
Trial: 10974130
Drug: Indomethacin and
RxNorm normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Indomethacin and Ibuprofen
Trial: 8781823
Drug: Bamiphylline (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bamiphylline (5 mg.kg‐1)
Trial: 8331207
Drug: Intravenous ceftazidime
RxNorm normalized name: Ceftazidime
DrugBank: Ceftazidime (DB00438)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous ceftazidime 1 g
Trial: 8331207
Drug: Intraperitoneal ceftazidime
RxNorm normalized name: Ceftazidime
DrugBank: Ceftazidime (DB00438)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intraperitoneal ceftazidime 1 g
Trial: 2867861
Drug: Almitrine (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Almitrine (3 mg/kg single dose, oral)
Trial: 30400221
Drug: Creatine supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Creatine supplementation (20 g for 6 days followed by 2 g until the end of the study)
Trial: 21985440
Drug: Prefabricated oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prefabricated oral appliance (R)
Trial: 21358487
Drug: Individually administered
RxNorm normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Individually administered physical therapy (IAPT)
Trial: 17183729
Drug: Atorvastatin (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin (40 mg)
Trial: 12860866
Drug: Nisoldipine 40
RxNorm normalized name: nisoldipine 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nisoldipine 40 mg once daily
Trial: 9273229
Drug: Recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recombinant human erythropoietin (rHuEPO) administered subcutaneously at a dose of 2000 U twice weekly (group II)
Trial: 30341345
Drug: Tenofovir disoproxil
RxNorm normalized name: Tenofovir Disoproxil
DrugBank: Tenofovir disoproxil (DB00300)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tenofovir disoproxil fumarate (TDF), oral dose 300 mg/day, initiated at 24 weeks of gestation and continued to 4 weeks after delivery
Trial: 30341345
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no TDF treatment)
Trial: 25176317
Drug: Clinic-based intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clinic-based intervention including educational, organizational, and behavioral components administered by trained lay personnel.
Trial: 22574965
Drug: Intense pulsed
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intense pulsed light (IPL) and fractional photothermolysis (FP) combination treatment
Trial: 20860133
Drug: Simo Decoction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simo Decoction Oral Liquid
Trial: 7801949
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of i.v. nitroglycerin (150 micrograms) and metoclopramide (20‐mg bolus)
Trial: 3082230
Drug: praziquantel (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: praziquantel (40 mg/kg)
Trial: 91436
Drug: Induction chemotherapy
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction chemotherapy consisting of bleomycin, vinblastine, Adriamycin, and cis‐dichlorodiammineplatinum(II)
Trial: 23507228
Drug: Blueberries (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blueberries (300 g)
Trial: 15152896
Drug: Diphenhydramine 50
RxNorm normalized name: diphenhydrAMINE 50 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diphenhydramine 50 mg (active control)
Trial: 3073625
Drug: Flurbiprofen (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flurbiprofen (100 mg x 2 for 5 days)
Trial: 3073625
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic acid (1.5 g x 3 for 3 days, 1 g x 2 days 4 and 5)
Trial: 25167960
Drug: 1.1 mg
RxNorm normalized name: menthol 1.1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.1 mg folic acid
Trial: 12702070
Drug: PUVA and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PUVA and topical calcipotriol
Trial: 1397915
Drug: Low sodium
RxNorm normalized name: Slow Sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low sodium cleansing solution
Trial: 11540865
Drug: d-fenfluramine (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: d-fenfluramine (15 mg p.o., twice daily)
Trial: 17927576
Drug: Retinoic acid
RxNorm normalized name: Retinoic acid
DrugBank: Tretinoin (DB00755)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Retinoic acid therapy
Trial: 15784032
Drug: Indomethacin (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin (25 mg, three times daily for 6 months)
Trial: 1754846
Drug: Colloidal bismuth
RxNorm normalized name: Colloidal bismuth subcitrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colloidal bismuth subcitrate (CBS), two tablets twice daily for 4 weeks
Trial: 7022484
Drug: Sodium meclofenamate
RxNorm normalized name: Meclofenamate Sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium meclofenamate (300 mg per day)
Trial: 7022484
Drug: Aspirin (3.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (3.6 g per day)
Trial: 28951663
Drug: 800 mg
RxNorm normalized name: bran 800 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800 mg i.v. ibuprofen
Trial: 28951663
Drug: saline without
FDA approved: no
EMA approved: no
PMDA approved: no
Description: saline without ibuprofen
Trial: 27290966
Drug: High-dose remifentanil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose remifentanil infusion
Trial: 27290966
Drug: Low-dose remifentanil
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose remifentanil infusion
Trial: 19045974
Drug: Community Treatment
RxNorm normalized name: ALCOHOL 80 mL in 100 mL TOPICAL LIQUID [Sanitizing Liquid for Community Support]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Community Treatment by Experts (CTBE)
Trial: 22954842
Drug: Virtual Reality
RxNorm normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Virtual Reality Exposure Therapy (VRE) administered for 10 treatment sessions over 5 weeks
Trial: 30005843
Drug: Virtual Reality
RxNorm normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Virtual Reality Exposure Therapy (VRE)
Trial: 9801179
Drug: Ondansetron hydrochloride,
RxNorm normalized name: Ondansetron Hydrochloride, 4 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ondansetron hydrochloride, 4 mg intravenously
Trial: 31987233
Drug: Sucrose (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sucrose (0.5 ml of oral 24% sucrose)
Trial: 31987233
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of sucrose and music
Trial: 26691576
Drug: Adjunctive sarcosine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjunctive sarcosine (2 g/day) plus benzoate (1 g/day)
Trial: 26691576
Drug: Sarcosine (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sarcosine (2 g/day)
Trial: 25291409
Drug: Oral prednisolone
RxNorm normalized name: prednisolone Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral prednisolone 0.25 mg/kg/d for 7 days
Trial: 21541462
Drug: Intradermal (ID)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal (ID) vaccine administration
Trial: 11419884
Drug: Aspirin 81
RxNorm normalized name: aspirin 81 MG
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin 81 mg every third day
Trial: 3539708
Drug: Ranitidine therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine therapy (150 mg bd)
Trial: 30463324
Drug: 500 mg/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg/d Sensoril® (S500)
Trial: 24246116
Drug: Lurasidone monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lurasidone monotherapy (20-60mg/d)
Trial: 24246116
Drug: Lurasidone monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lurasidone monotherapy (80-120mg/d)
Trial: 24246116
Drug: Lurasidone adjunctive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lurasidone adjunctive therapy (20-120mg/d)
Trial: 20569447
Drug: Methylphenidate (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylphenidate (0.5 mg/kg/day)
Trial: 6734037
Drug: Acetaminophen (650
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen (650 mg)
Trial: 17709207
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of acetaminophen (325 mg) and tramadol (37.5 mg)
Trial: 9438767
Drug: Pentoxifylline (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentoxifylline (1 mg/kg of body weight per hour; maximum, 1800 mg/d)
Trial: 8586774
Drug: Psyllium-enriched Step
RxNorm normalized name: STEP 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psyllium-enriched Step I diet (3.2 g of soluble fiber per 1-oz box of cereal, 2 boxes per day)
Trial: 8586774
Drug: Step I
RxNorm normalized name: Bexxar Dosimetric Step Iodine I-131 Tositumomab Solution for Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Step I control diet (less than 0.5 g of soluble fiber per 1-oz box of cereal, 2 boxes per day)
Trial: 790146
Drug: Intensive consolidation
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive consolidation therapy in a protected environment unit with antibiotic prophylaxis
Trial: 790146
Drug: Intensive consolidation
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive consolidation therapy in a protected environment unit without antibiotic prophylaxis
Trial: 790146
Drug: Early consolidation
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early consolidation therapy
Trial: 1581404
Drug: Conventional maintenance
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional maintenance therapy
Trial: 28323986
Drug: Chronic intranasal
RxNorm normalized name: Chromic Chloride
DrugBank: Chromic chloride (DB09129)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chronic intranasal insulin treatment (40 IU, 4 times daily)
Trial: 27045264
Drug: Tadalafil 5
RxNorm normalized name: tadalafil 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tadalafil 5 mg once daily (OaD)
Trial: 23404788
Drug: Taspoglutide 20
RxNorm normalized name: Taspoglutide
DrugBank: Taspoglutide (DB14027)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taspoglutide 20 mg (10 mg for first 4 weeks)
Trial: 16979854
Drug: Sensory‐motor‐oral stimulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sensory‐motor‐oral stimulation and non‐nutritive sucking
Trial: 11699736
Drug: Braun Oral-B
RxNorm normalized name: bran Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Braun Oral-B children's power toothbrush (D10)
Trial: 8199828
Drug: Intravesical instillations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravesical instillations with immuno‐ or chemotherapy
Trial: 31387606
Drug: Verubecestat 12
RxNorm normalized name: Verubecestat
DrugBank: Verubecestat (DB12285)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verubecestat 12 mg
Trial: 31387606
Drug: Verubecestat 40
RxNorm normalized name: Verubecestat
DrugBank: Verubecestat (DB12285)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verubecestat 40 mg
Trial: 28784336
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg oestrogen daily (low-dose group)
Trial: 28784336
Drug: 6 mg
RxNorm normalized name: boron 6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 mg oestrogen daily (high-dose group)
Trial: 15140632
Drug: Isradipine (0-10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isradipine (0-10 mg/70 kg, p.o.)
Trial: 15140632
Drug: Dextromethorphan (0-60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dextromethorphan (0-60 mg/70 kg, p.o.)
Trial: 12658070
Drug: Naloxone (0.15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naloxone (0.15 mg/70 kg, i.m.)
Trial: 23860288
Drug: Carbohydrate supplementation
RxNorm normalized name: pyrrolidone carboxylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbohydrate supplementation (0.5 g·kg·h)
Trial: 20942276
Drug: Deanxit, oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deanxit, oral administration for eight weeks.
Trial: 18769066
Drug: ORS +
RxNorm normalized name: Orserdu
DrugBank: Elacestrant (DB06374)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ORS + 25 g PHGG
Trial: 18769066
Drug: ORS +
RxNorm normalized name: Orserdu
DrugBank: Elacestrant (DB06374)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ORS + 50 g PHGG
Trial: 16948480
Drug: Whey protein
RxNorm normalized name: Whey protein
DrugBank: Whey (DB18685)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whey protein (1.2 g/kg body mass whey protein + 0.3 g/kg body mass sucrose powder, N = 9: 6 female, 3 male)
Trial: 14514574
Drug: Vitamin C
RxNorm normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin C (2 g/day) for 4 weeks
Trial: 1570227
Drug: Controlled-release morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Controlled-release morphine 30-mg tablets (MSC) administered orally
Trial: 6399444
Drug: Four drugs
RxNorm normalized name: Four-Way
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four drugs commonly used for pain relief (specific drugs not mentioned)
Trial: 17429632
Drug: Conventional 2-hour
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional 2-hour infusion of l-HOP (oxaliplatin)
Trial: 23421309
Drug: Sucrose solution
RxNorm normalized name: TootSweet 24% Oral Sucrose Solution
DrugBank: Sucrose (DB02772)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sucrose solution (control)
Trial: 8860096
Drug: Insulin sensitivity
RxNorm normalized name: Fluorimax Sensitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin sensitivity index (S(I))
Trial: 6376229
Drug: Cimetidine 1
RxNorm normalized name: cimetidine 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine 1 g, trimipramine 50 mg, prostaglandin E1 analogue 800 or 200 micrograms, low-dose antacid or placebo (antiulcer treatment)
Trial: 25060950
Drug: B0.25 group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: B0.25 group (3.75mg hyperbaric bupivacaine 2.5mg/ml)
Trial: 11369834
Drug: Treatment of
RxNorm normalized name: DRUGS FOR TREATMENT OF LEPRA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment of established severe anaemia in patients with ESRD
Trial: 22506497
Drug: Local sequential
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local sequential context provided by preceding facial expressions
Trial: 9357378
Drug: Azelastine nasal
RxNorm normalized name: azelastine nasal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azelastine nasal spray (2 sprays per nostril bid)
Trial: 8238830
Drug: Propofol 2
RxNorm normalized name: propofol 20 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol 2 mg.kg‐1 and Alfentanil 50 micrograms.kg‐1
Trial: 6354230
Drug: i.v. infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. infusion of insulin, 70 mu. kg‐1h‐1 for the first 60 min and 35 mu. kg‐1h‐1 subsequently
Trial: 27239994
Drug: Standard oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard oral management (S)
Trial: 22661278
Drug: Reduced-intensity modified
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reduced-intensity modified constraint-induced movement therapy (mCIMT)
Trial: 17666600
Drug: IV ferric
RxNorm normalized name: Ferric Oxide
DrugBank: Ferric oxide (DB11576)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV ferric carboxymaltose (less than or equal to 1,000 mg over 15 minutes, repeated weekly)
Trial: 17666600
Drug: Oral ferrous
RxNorm normalized name: ferrous fumarate Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral ferrous sulfate (FeSO(4) 325 mg orally thrice daily for 6 weeks)
Trial: 8814685
Drug: Carboplatin 400
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carboplatin 400 mg/m2 as a single agent (CB)
Trial: 8814685
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of carboplatin 300 mg/m2, epirubicin 50 mg/m2 and cyclophosphamide 500 mg/m2 (CB‐EC)
Trial: 28648477
Drug: Early antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early antibiotic administration (mean TTA 4.35h, 58.5% received first dose within 4h)
Trial: 14971863
Drug: Clozapine (450
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clozapine (450 mg/day)
Trial: 14971863
Drug: Olanzapine (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olanzapine (50 mg/day)
Trial: 9071645
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone (hGH) treatment for 2 years
Trial: 15121021
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg iv ibandronate injections
Trial: 9461704
Drug: Thrombolytic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thrombolytic therapy with monitoring of myoglobin concentration, CPK, and CK-MB activity.
Trial: 27370230
Drug: Metformin with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin with atorvastatin
Trial: 23608625
Drug: Biotene OralBalance®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biotene OralBalance® gel
Trial: 19931408
Drug: human insulin
RxNorm normalized name: Human insulin
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: human insulin B‐chain in incomplete Freund's adjuvant (IFA)
Trial: 16500657
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Sulphadoxine-pyrimethamine and Artesunate (SP+AS)
Trial: 14645311
Drug: Olanzapine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olanzapine (5 to 20 mg/d) with prophylactic benztropine (1 to 4 mg/d)
Trial: 14645311
Drug: Haloperidol (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haloperidol (5 to 20 mg/d)
Trial: 31109198
Drug: Cannabidiol (CBD)
RxNorm normalized name: cannabidiol (CBD)
DrugBank: Cannabidiol (DB09061)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Cannabidiol (CBD) 400 or 800 mg, once daily for 3 consecutive days
Trial: 25907999
Drug: 0.0015% Tafluprost
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.0015% Tafluprost ophthalmic solution
Trial: 21831448
Drug: Adjunctive creatine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjunctive creatine 4 g daily for 8 weeks
Trial: 11262678
Drug: Post administration
RxNorm normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post administration of the VCM1 questionnaire